文献速递心脑血管急症

替格瑞洛与氯吡格雷在有症状外周动脉疾病中的比较

Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease.
PubMed 文献 · N Engl J Med · 2016-11-13
一句话结论在有症状外周动脉疾病患者中,替格瑞洛未能显示在减少心血管事件方面优于氯吡格雷,大出血发生率相似。

该双盲、事件驱动试验纳入13,885例有症状外周动脉疾病患者,随机接受替格瑞洛(90 mg 每日两次)或氯吡格雷(75 mg 每日一次)单药治疗。主要疗效终点为心血管死亡、心肌梗死或缺血性卒中的复合终点,中位随访30个月。替格瑞洛组主要疗效终点发生率为10.8%,氯吡格雷组为10.6%(HR 1.02;95%CI 0.92-1.13;P=0.65)。两组急性肢体缺血发生率均为1.7%,大出血发生率均为1.6%。结论提示替格瑞洛未显示优于氯吡格雷。

要点

  • 在13,885例有症状外周动脉疾病患者中,替格瑞洛组主要疗效终点(心血管死亡、心肌梗死或缺血性卒中)发生率为10.8%,氯吡格雷组为10.6%(HR 1.02;95%CI 0.92-1.13;P=0.65)。
  • 两组急性肢体缺血发生率均为1.7%(HR 1.03;95%CI 0.79-1.33;P=0.85)。
  • 两组大出血发生率均为1.6%(HR 1.10;95%CI 0.84-1.43;P=0.49)。
  • 患者纳入标准为踝臂指数(ABI)≤0.80或曾接受下肢血运重建;平均基线ABI为0.71,76.6%有间歇性跛行,4.6%有严重肢体缺血。
  • 中位随访30个月,替格瑞洛(90 mg 每日两次)未显示在减少心血管事件方面优于氯吡格雷(75 mg 每日一次)。

适用人群与场景

  • 有症状外周动脉疾病患者,纳入标准为踝臂指数(ABI)≤0.80或曾接受下肢血运重建。
  • 共13,885例患者,中位年龄66岁,72%为男性;43%基于ABI入选,57%基于既往血运重建入选。
  • 平均基线ABI为0.71,76.6%有间歇性跛行,4.6%有严重肢体缺血。

诊断标准与关键阈值

  • 纳入标准:踝臂指数(ABI)≤0.80或曾接受下肢血运重建。

处置流程与药物剂量

  • 替格瑞洛组:替格瑞洛90 mg 每日两次口服单药治疗。
  • 氯吡格雷组:氯吡格雷75 mg 每日一次口服单药治疗。

研究设计与关键结果

  • 研究类型:双盲、事件驱动试验;样本量13,885例;人群为有症状外周动脉疾病患者;干预为替格瑞洛90 mg 每日两次 vs 氯吡格雷75 mg 每日一次;中位随访30个月。
  • 主要疗效终点(心血管死亡、心肌梗死或缺血性卒中复合终点):替格瑞洛组751/6930例(10.8%)vs 氯吡格雷组740/6955例(10.6%),HR 1.02(95%CI 0.92-1.13),P=0.65。
  • 急性肢体缺血:两组均为1.7%,HR 1.03(95%CI 0.79-1.33),P=0.85。
  • 大出血(主要安全终点):两组均为1.6%,HR 1.10(95%CI 0.84-1.43),P=0.49。

证据类型、等级与局限

  • 证据类型:随机对照试验(双盲、事件驱动)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于有症状外周动脉疾病患者,替格瑞洛90 mg 每日两次未显示在减少心血管死亡、心肌梗死或缺血性卒中方面优于氯吡格雷75 mg 每日一次。
  • 替格瑞洛与氯吡格雷的大出血发生率相似(均为1.6%)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Peripheral artery disease is considered to be a manifestation of systemic atherosclerosis with associated adverse cardiovascular and limb events. Data from previous trials have suggested that patients receiving clopidogrel monotherapy had a lower risk of cardiovascular events than those receiving aspirin. We wanted to compare clopidogrel with ticagrelor, a potent antiplatelet agent, in patients with peripheral artery disease.

METHODS: In this double-blind, event-driven trial, we randomly assigned 13,885 patients with symptomatic peripheral artery disease to receive monotherapy with ticagrelor (90 mg twice daily) or clopidogrel (75 mg once daily). Patients were eligible if they had an ankle-brachial index (ABI) of 0.80 or less or had undergone previous revascularization of the lower limbs. The primary efficacy end point was a composite of adjudicated cardiovascular death, myocardial infarction, or ischemic stroke. The primary safety end point was major bleeding. The median follow-up was 30 months.

RESULTS: The median age of the patients was 66 years, and 72% were men; 43% were enrolled on the basis of the ABI and 57% on the basis of previous revascularization. The mean baseline ABI in all patients was 0.71, 76.6% of the patients had claudication, and 4.6% had critical limb ischemia. The primary efficacy end point occurred in 751 of 6930 patients (10.8%) receiving ticagrelor and in 740 of 6955 (10.6%) receiving clopidogrel (hazard ratio, 1.02; 95% confidence interval [CI], 0.92 to 1.13; P=0.65). In each group, acute limb ischemia occurred in 1.7% of the patients (hazard ratio, 1.03; 95% CI, 0.79 to 1.33; P=0.85) and major bleeding in 1.6% (hazard ratio, 1.10; 95% CI, 0.84 to 1.43; P=0.49).

CONCLUSIONS: In patients with symptomatic peripheral artery disease, ticagrelor was not shown to be superior to clopidogrel for the reduction of cardiovascular events. Major bleeding occurred at similar rates among the patients in the two trial groups. (Funded by AstraZeneca; EUCLID ClinicalTrials.gov number, NCT01732822 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Hiatt WR, Fowkes FG, Heizer G, et al. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. N Engl J Med. 2016. PMID: 27959717. doi:10.1056/NEJMoa1611688

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。